MSLN and exocrine pancreatic carcinoma: The most experience with CAR T cells in PDAC patients has been with targeting mesothelin since approximately 80% of pancreatic carcinomas express mesothelin and, as a result, has become a key target for CAR T cell therapy trials [16],[17] (NCT03323944).